April 28, 2011
Posted by Admin
ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration
The company issued the following press release today.
UCLA’s Jules Stein Eye Institute to be a Site for Phase 1/2 Trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-related Macular Dystrophy (Dry AMD)
MARLBOROUGH, Mass. – April 28, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced [...]